September 16, 2024 08:00 AM EDTUpdated 08:19 AM
Financing
Startups

Biotech IPO mar­ket still in flux fol­low­ing flashy Fri­day triple­head­er

Kyle LaHucik

Senior Reporter

Three clin­i­cal-stage biotechs, three up­sized of­fer­ings and three first-day share spikes.

Last Fri­day’s biotech IPO triple­head­er was a mul­ti­year rar­i­ty for an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times